FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings per share of ($3.04) for the year, up from their prior forecast of ($3.25). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q4 2024 earnings at ($0.94) EPS, Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.18) EPS and FY2026 earnings at ($4.13) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 28.05%. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. The company’s revenue was down 20.9% on a year-over-year basis.

KYMR has been the topic of several other research reports. Guggenheim raised their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday. Oppenheimer raised their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. B. Riley upped their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a report on Monday, August 26th. Finally, Morgan Stanley boosted their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 14th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $49.15.

Kymera Therapeutics Stock Up 0.6 %

Shares of NASDAQ KYMR opened at $46.47 on Monday. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $53.27. The firm has a market cap of $2.87 billion, a PE ratio of -19.86 and a beta of 2.21. The business has a fifty day simple moving average of $47.04 and a two-hundred day simple moving average of $40.75.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KYMR. Harbor Capital Advisors Inc. increased its stake in shares of Kymera Therapeutics by 30.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company’s stock valued at $1,908,000 after purchasing an additional 9,292 shares in the last quarter. Integrated Advisors Network LLC purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $294,000. China Universal Asset Management Co. Ltd. increased its position in shares of Kymera Therapeutics by 72.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,422 shares of the company’s stock valued at $588,000 after buying an additional 5,214 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $61,000.

Insiders Place Their Bets

In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.